As of 2024-12-11, the EV/EBITDA ratio of Emergent BioSolutions Inc (EBS) is 41.85. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EBS's latest enterprise value is 979.19 mil USD. EBS's TTM EBITDA according to its financial statements is 23.40 mil USD. Dividing these 2 quantities gives us the above EBS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative Enterprise Value.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 12.1x | 11.4x |
| Forward P/E multiples | 11.6x - 17.3x | 14.4x |
| Fair Price | (4.88) - (1.99) | (3.89) |
| Upside | -156.7% - -123.1% | -145.2% |
| Date | EV/EBITDA |
| 2024-12-09 | 42.19 |
| 2024-12-06 | 42.77 |
| 2024-12-05 | 43.10 |
| 2024-12-04 | 43.74 |
| 2024-12-03 | 43.42 |
| 2024-12-02 | 44.69 |
| 2024-11-29 | 45.34 |
| 2024-11-27 | 45.32 |
| 2024-11-26 | 45.13 |
| 2024-11-25 | 44.72 |
| 2024-11-22 | 43.86 |
| 2024-11-21 | 43.67 |
| 2024-11-20 | 42.47 |
| 2024-11-19 | 41.06 |
| 2024-11-18 | 41.82 |
| 2024-11-15 | 39.79 |
| 2024-11-14 | 43.37 |
| 2024-11-13 | 44.99 |
| 2024-11-12 | 47.12 |
| 2024-11-11 | 49.63 |
| 2024-11-08 | 49.16 |
| 2024-11-07 | 47.38 |
| 2024-11-06 | 43.21 |
| 2024-11-05 | 42.66 |
| 2024-11-04 | 42.22 |
| 2024-11-01 | 43.03 |
| 2024-10-31 | 42.89 |
| 2024-10-30 | 44.14 |
| 2024-10-29 | 43.51 |
| 2024-10-28 | 44.30 |
| 2024-10-25 | 42.59 |
| 2024-10-24 | 42.89 |
| 2024-10-23 | 42.17 |
| 2024-10-22 | 43.28 |
| 2024-10-21 | 45.48 |
| 2024-10-18 | 43.56 |
| 2024-10-17 | 43.07 |
| 2024-10-16 | 43.12 |
| 2024-10-15 | 43.19 |
| 2024-10-14 | 42.75 |
| 2024-10-11 | 42.17 |
| 2024-10-10 | 41.48 |
| 2024-10-09 | 42.59 |
| 2024-10-08 | 43.26 |
| 2024-10-07 | 43.21 |
| 2024-10-04 | 43.56 |
| 2024-10-03 | 42.61 |
| 2024-10-02 | 43.19 |
| 2024-10-01 | 41.52 |
| 2024-09-30 | 41.24 |